A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with
 diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
Inclusion Criteria:

 -  Patients meeting the Rome III Diagnostic Criteria

 -  Loose (mushy) or watery stools within the last 3 months

 -  Abdominal discomfort and/or pain during their non-menstrual period

 Exclusion Criteria:

 -  Patients with a history of surgical resection of the stomach, small intestine or large
 intestine

 -  Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's
 disease or colitis ulcerative)

 -  Patients with a history or current diagnosis of colitis ischemic

 -  Patients with a current diagnosis of enteritis infectious

 -  Patients with a current diagnosis of hyperthyroidism or hypothyroidism

 -  Patients who are currently participating in another clinical trial (including a
 post-marketing clinical study) or those who participated in another clinical trial
 (including a post-marketing clinical study) within 12 weeks before the study

 -  Patients with a history or current diagnosis of malignant tumor

 -  Patients with a history of abuse of drugs or alcohol within 1 year or those who are
 currently abusing them